Rongshi Li is a Professor at UNMC Center for Drug Discovery, Department of Pharmaceutical Sciences, College of Pharmacy, Fred and Pamela Buffett Cancer Center, and Center for Staphylococcal Research, University of Nebraska Medical Center, USA. Dr. Li obtained his B.S. and M.S. from Shenyang College of Pharmacy (now Shenyang Pharmaceutical University), and Ph.D. from Dalhousie University in Canada. Dr. Li started his career in Biotech industry advanced from Scientist to Senior Vice President after his postdoctoral training in the Department of Pharmaceutical Chemistry, University of California San Francisco in 1995. In 2008, Dr. Li began his academic career at H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida. In 2013, Dr. Li was recruited to University of Nebraska Medical Center. Dr. Li has over 200 publications including peer-reviewed articles, invited reviews, US and PCT (World) patents, books, book chapters, editorial, invited lectures and published abstracts in the universities and research institutions throughout the world and in US national and international symposia. Dr. Li was a Guest Editor for a special issue of natural product-based drug discovery for Medicinal Research Reviews (Impact Factor: 9.135) and peer-reviewers for over 30 scientific journals. Recently, Dr. Li received 2016 Distinguished Scientist Award, 2014 and 2016 Inventions Awards,

and 2013 NIH Grant Award. Dr. Li’s research interests include fragment-based and structure guided design of enzyme inhibitors and disruptors of protein-protein interactions; synthesis of natural products and their derivatives for drug discovery; hit-to-lead and lead optimization using organic/medicinal chemistry; drug design and discovery in anticancer and antibiotic therapeutics.

报告内容简介：

This talk will present our resent research of antibiotic and anti-cancer drug discovery. Using fragment based and structure guided approaches, we designed, synthesized and patented several novel series of natural product derivatives. Through SAR optimization, we discovered potent compounds as Mcl-1 inhibitors, CXCL-12 antagonists and ROCK inhibitors for potential cancer therapy and anti-MRSA and anti-biofilm agents for antibacterial indications. These compounds have good physicochemical and drug properties as well as favorable pharmacokinetic profiles.